A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Clinical trial NCT04450329 · COMPLETED
Trial details
- NCT number
- NCT04450329
- Sponsor
- Samsung Bioepis Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-23
- Primary completion
- 2021-04-15
- Enrollment
- 449
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.